Please login to the form below
Valrox
This page shows the latest Valrox news and features for those working in and with pharma, biotech and healthcare.
Presidential hopeful Bernie Sanders criticises BioMarin’s gene therapy price
The new therapy, Valrox (valoctocogene roxaparvovec), improved levels of clotting Factor VIII sufficiently in eight of 20 adults with severe haemophilia A treated over three years in BioMarin’s phase 3 ... Now, BioMarin is eyeballing a $2m-$3m
Latest news
-
Sangamo steps up BioMarin chase with haemophilia gene therapy data
Sangamo is adamant that it is still in contention in the haemophilia A gene therapy market, despite BioMarin’s stated plan of filing for approval of its valoctocogene roxaparvovec or ‘valrox’ ... Three-year data on its candidate were reported in May
-
Roche’s Hemlibra scores broader NHS funding
BioMarin is in pole position with its candidate valrox, which it plans to submit by the end of 2019.
-
BioMarin ticks over in Q2 ahead of gene therapy filing
The game-changer for the company, however, is its gene therapy for haemophilia A, valoctocogene roxaparvovec, known as valrox. ... valrox and vosoritide, its late stage candidate for achondroplasia, (the most common form of dwarfism) which they say have
-
ACPs to lead gene therapies in haemophilia market growth
BioMarin’s ValRox, which is expected to launch as early as 2020, and Spark Therapeutics’ SPK-8011 for haemophilia A, and uniQure’s AMT-061 and Pfizer/Spark Therapeutics’ SPK-9001 ... Therefore, first-to-market advantage will drive commercial
-
New results back Sangamo, UniQure haemophilia gene therapies
It’s a case of so far, so good with SB-525 as Sangamo and Pfizer set off in pursuit of BioMarin’s valrox candidate, which is already in a phase
More from news
Approximately 2 fully matching, plus 11 partially matching documents found.
Latest Intelligence
-
Keeping up with the developing regulatory requirements for gene and cell therapies
The FDA’s requirement on Biomarin to provide an additional two years of clinical data of Valrox before approval signals an increase in regulatory scrutiny for the regenerative medicine industry.
-
Cortellis Drugs to Watch in 2020 report
Valrox is in regulatory review in the US, with a PDUFA date of 21 August 2020, with an MAA also being reviewed in the EU. ... For this reason, even if the penetration is modest, Valrox could post significant revenue.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- FDA external report recommends actions to address US opioid crisis
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- The increasing value of rare disease trials
- Wrapping up EAU with a Look at Medscape’s Urology Impact
- MHRA to introduce new UK clinical trials framework
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Congress is in session – how companies are boosting their impact and engagement
- AstraZeneca announces major expansion of Canadian research footprint
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
